Lymphoma Coalition publishes research on the experiences of patients and care partners based on learnings from the Global Patient Survey on Lymphomas and CLL (GPS) and other projects.
It is imperative the issues raised by patients and their care partners through the biennial survey, interviews, focus groups and other initiatives are conveyed to the medical and research communities to improve care moving forward.
[{"id":39998,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/an-investigation-into-the-preferences-of-patients-regarding-the-use-of-telemedicine-stemming-from-the-covid-19-pandemic\/","name":"an-investigation-into-the-preferences-of-patients-regarding-the-use-of-telemedicine-stemming-from-the-covid-19-pandemic","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Patient-Preferences-for-Telemedicine-During-the-COVID19-Pandemic.png","alt":""},"title":"Patient Preferences for Telemedicine During the COVID-19 Pandemic","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Jun 11, 2023","dateGMT":"2023-06-11 17:31:00","modifiedDate":"2025-10-14 14:52:48","modifiedDateGMT":"2025-10-14 14:52:48","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/covid\/\" rel=\"category tag\">COVID<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/covid\/\" rel=\"category tag\">COVID<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":2,"sec":13},"status":"publish","excerpt":"Accepted for publication at the EHA 2023 Hybrid Congress in Frankfurt, Germany from 8-11 June 2023. Telemedicine has become increasingly crucial for remote healthcare delivery, with telephone consultation (TC) and video consultation (VC) being two important modalities. However, there is limited knowledge about the preferences and experiences of patients with lymphoma or CLL (chronic lymphocytic leukemia). Understanding patient preferences and experiences is vital for successfully integrating telemedicine into clinical practice beyond the COVID-19 pandemic."},{"id":40010,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct\/","name":"barriers-to-clinical-trial-information-in-relapsed-refractory-lymphoma-patients-post-sct","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Demographic-Barriers-to-Clinical-Trial-Information-in-RR-Lymphoma-Patients-PostSCT.png","alt":""},"title":"Demographic Barriers to Clinical Trial Information in R\/R Lymphoma Patients Post-SCT","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 26, 2023","dateGMT":"2023-04-26 17:38:00","modifiedDate":"2025-10-14 14:54:06","modifiedDateGMT":"2025-10-14 14:54:06","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/treatmentsideeffects\/car-t-research\/\" rel=\"category tag\">CAR-T Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/psychosocial\/\" rel=\"category tag\">Psychosocial<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/relapserefractory\/\" rel=\"category tag\">Relapse\/Refractory<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":46},"status":"publish","excerpt":"Presented at the 49th Annual European Society for Blood and Marrow Transplantation (EBMT) meeting, in Paris France, 22-26 April 2023. Lymphoma Coalition (LC) supports almost 90 patient organizations across more than 50 countries. LC\u2019s overarching goal is to facilitate a community of patient organizations supporting efforts to help patients with lymphoma receive optimal care and support.\n\nStem Cell Transplant (SCT) and clinical trials involving new treatments provide increased opportunities for longer-lasting remission in patients with lymphoma with relapsed or refractory disease. However, not all patients are given information or the opportunity to access clinical trials.\n\nThis study investigates the potential socioeconomic barriers to receiving information on clinical trials or the opportunity to participate in them for patients with lymphoma who have previously received SCT."},{"id":40016,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/identifying-factors-that-affect-barriers-to-lymphoma-treatment-during-the-covid-19-pandemic\/","name":"identifying-factors-that-affect-barriers-to-lymphoma-treatment-during-the-covid-19-pandemic","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Barriers-to-Lymphoma-Treatment-during-the-COVID-19-Pandemic.png","alt":""},"title":"Barriers to Lymphoma Treatment during the COVID-19 Pandemic","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Apr 19, 2023","dateGMT":"2023-04-19 17:44:00","modifiedDate":"2025-10-14 14:58:39","modifiedDateGMT":"2025-10-14 14:58:39","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/covid\/\" rel=\"category tag\">COVID<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/covid\/\" rel=\"category tag\">COVID<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":7},"status":"publish","excerpt":"Presented at the AACR Annual Meeting in Orlando, Florida 14 \u2013 19 April 2023. Lymphoma Coalition (LC) supports over 80 patient organizations across more than 50 countries. LC's overarching goal is to facilitate a community of patient organizations supporting efforts to help patients with lymphoma receive care and support.\n\nBarriers to accessing treatment therapy for patients with lymphoma are an essential topic across the globe.\n\nLC's biennial Global Patient Survey (GPS) aims to understand the barriers faced by patients with lymphoma in seeking medical attention or accessing treatment. With the added challenge posed by the COVID-19 pandemic, this study aimed to rank the influence of core demographic variables in their ability to predict barriers to lymphoma treatment in 2020 and 2022."},{"id":40027,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/impact-of-ageing-on-the-survivorship-experiences-of-patients-with-hodgkin-lymphoma\/","name":"impact-of-ageing-on-the-survivorship-experiences-of-patients-with-hodgkin-lymphoma","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/2025-09-17-13_44_46-Greenshot.png","alt":""},"title":"Impact of Ageing on Survivorship in Hodgkin Lymphoma","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Oct 24, 2022","dateGMT":"2022-10-24 17:54:00","modifiedDate":"2025-10-14 15:06:42","modifiedDateGMT":"2025-10-14 15:06:42","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/hodgkinlymphoma\/\" rel=\"category tag\">Hodgkin Lymphoma<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/qualityoflife\/\" rel=\"category tag\">Quality of Life<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/survivorship\/\" rel=\"category tag\">Survivorship<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/hodgkinlymphoma\/\" rel=\"category tag\">Hodgkin Lymphoma<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/\" rel=\"category tag\">Psychosocial & Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/qualityoflife\/\" rel=\"category tag\">Quality of Life<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/subtype-specific\/\" rel=\"category tag\">Subtype-Specific<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/psychosocialqualityoflife\/survivorship\/\" rel=\"category tag\">Survivorship<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":23},"status":"publish","excerpt":"Presented at the the International Symposium on Hodgkin Lymphoma (ISHL12) in Cologne, Germany, from October 22-24. Hodgkin lymphoma (HL) often affects young adults and has one of the highest cure rates among all cancers, leading to an increasing number of survivors each year.\n\nIts treatment may cause long-term or late effects, which can impact a patient\u2019s overall health and quality of life. These effects raise concerns about survivorship care and long-term management.\n\nThis study uses data from the Lymphoma Coalition (LC) 2022 Global Patient Survey (GPS) on lymphoma and CLL to examine the survivorship experiences of HL patients in remission."},{"id":40043,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/impact-of-national-health-expenditure-on-lymphoma-and-cll-diagnosis-in-europe\/","name":"impact-of-national-health-expenditure-on-lymphoma-and-cll-diagnosis-in-europe","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/comparitive-study-oni-health-expenditure-abstract-image.png","alt":""},"title":"Impact of National Health Expenditure on Lymphoma and CLL Support in Europe","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Feb 11, 2022","dateGMT":"2022-02-11 18:18:00","modifiedDate":"2025-10-14 15:07:26","modifiedDateGMT":"2025-10-14 15:07:26","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/barrierstotreatment\/\" rel=\"category tag\">Barriers to Treatment<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":13},"status":"publish","excerpt":"Presented during the \u201cBest Abstract Session\u201d at the 5th European CAR-T Cell Meeting in Rotterdam, The Netherlands, February 9-11. Lymphomas are a mixed group of cancers with a wide variety of clinical presentations, ranging from an indolent course to an aggressive disease. They are often challenging to diagnose. A long time to diagnosis of lymphoma or CLL can increase patient anxiety and negatively impact survival and quality of life.\n\nCommunication with healthcare professionals is also a key part of the patient experience at diagnosis, as patients rely on this information to make sense of their condition and care."},{"id":40053,"link":"https:\/\/lymphoma-stg.clarovantdigital.com\/age-related-differences-in-the-informational-experiences-and-needs-of-patients-with-lymphoma-results-from-the-2020-global-patient-survey\/","name":"age-related-differences-in-the-informational-experiences-and-needs-of-patients-with-lymphoma-results-from-the-2020-global-patient-survey","thumbnail":{"url":"https:\/\/lymphoma-stg.clarovantdigital.com\/wp-content\/uploads\/Age-Related-Differences-in-the-Informational-Experiences-and-Needs-of-Patients-with-Lymphoma-Results-from-the-2020-Lymphoma-Coalition-Global-Patient-Survey.png","alt":""},"title":"Age-Related Differences in Information Needs of Patients with Lymphoma: Results from the 2020 Global Patient Survey","author":{"name":"","link":"https:\/\/lymphoma-stg.clarovantdigital.com\/author\/firstname lastname\/"},"date":"Dec 11, 2021","dateGMT":"2021-12-11 18:26:00","modifiedDate":"2025-10-14 15:08:06","modifiedDateGMT":"2025-10-14 15:08:06","commentCount":"0","commentStatus":"open","categories":{"coma":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/healthliteracy\/\" rel=\"category tag\">Health Literacy<\/a>, <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>","space":"<a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/\" rel=\"category tag\">Access to Care<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/accesstocare\/age\/\" rel=\"category tag\">Age<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/healthliteracy\/\" rel=\"category tag\">Health Literacy<\/a> <a href=\"https:\/\/lymphoma-stg.clarovantdigital.com\/category\/lc-research\/\" rel=\"category tag\">LC Research<\/a>"},"taxonomies":{"post_tag":""},"readTime":{"min":3,"sec":44},"status":"publish","excerpt":"Presented at the 63rd American Society of Hematology (ASH) conference on 11 December. Lymphomas most commonly occur in older adults but can occur in all age groups. Despite the shift towards patient-centered care, very little has been done to explore the informational needs of patients with lymphoma by age.\n\nIn this study, the Lymphoma Coalition (LC) describes age-related differences in the informational needs of patients with lymphoma using the 2020 LC Global Patient Survey (GPS)."}]